Aflibercept 8 mg first to safe sustained vision gains with bigger than 70% of sufferers extended to intervals between 16 and 24 weeks in moist age-linked macular degeneration at two years





12: 59 PM


No longer intended for U.S. and UK Media – Two-300 and sixty five days topline outcomes from the pivotal look PULSAR:


Outcomes from PULSAR existing lengthy duration of time efficacy of aflibercept 8 mg with extended dosing intervals reaching as a lot as 24 weeks and vision enhancements a corresponding to Eylea™ (aflibercept 2 mg) at fastened 8-weekly dosing over two years / Sufferers randomized at baseline to aflibercept 8 mg 16-week dosing routine obtained a median of 8.2 injections (4.6 fewer than Eylea (aflibercept 2 mg)) over two years / Security profile of aflibercept 8 mg in neovascular (moist) age-linked macular degeneration (nAMD) remains a corresponding to Eylea (aflibercept 2 mg) without a new signals identified

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button